California Pacific Medical Center

Running trials

• Recruiting

  INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

  NCT06965504· Abiomed Inc.· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Prilenia· Source

• Recruiting

  A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  NCT06890338· Phase 2· AbbVie· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Mirdametinib in Patients With Advanced NF1-mutant Melanoma

  NCT07237100· Phase 2· Kevin Kim, MD· Source

• Active, not recruiting

  Study of COYA 302 for the Treatment of ALS

  NCT07161999· Phase 2/3· Coya Therapeutics· Source

• Not yet recruiting

  Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

  NCT06973629· Phase 3· Brainstorm-Cell Therapeutics· Source

• Recruiting

  A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

  NCT06798012· Phase 2· Takeda· Source

• Active, not recruiting

  A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

  NCT06848088· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

  NCT06100276· Phase 1/2· UniQure Biopharma B.V.· Source

• Active, not recruiting

  A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

  NCT06517758· Phase 3· Novartis Pharmaceuticals· Source

• Enrolling by invitation

  A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF

  NCT06335082· Heart Rhythm Clinical and Research Solutions, LLC· Source

• Active, not recruiting

  Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

  NCT05902169· Phase 3· CarThera· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

  NCT06132958· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

  NCT05987332· Phase 2/3· IDEAYA Biosciences· Source

• Active, not recruiting

  Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

  NCT05822752· Phase 2· AbbVie· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Phase III Study of AK112 for NSCLC Patients

  NCT06396065· Phase 3· Summit Therapeutics· Source

• Active, not recruiting

  A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

  NCT05787587· Phase 1· IDEAYA Biosciences· Source

• Active, not recruiting

  Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  NCT05611931· Phase 3· Karyopharm Therapeutics Inc· Source

• Active, not recruiting

  Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

  NCT05462145· Kardium Inc.· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

  NCT05456685· Phase 2· AbbVie· Source

• Active, not recruiting

  Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

  NCT04526665· Phase 3· Ipsen· Source

• Recruiting

  Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

  NCT04427384· GT Medical Technologies, Inc.· Source

• Active, not recruiting

  HEALEY ALS Platform Trial - Master Protocol

  NCT04297683· Phase 2/3· Merit E. Cudkowicz, MD· Source

• Active, not recruiting

  A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

  NCT04008797· Phase 1/2· Eisai Inc.· Source

• Active, not recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

  NCT03796962· Phase 2· Xenon Pharmaceuticals Inc.· Source

• Recruiting

  Clinical Procedures to Support Research in ALS

  NCT03489278· University of Miami· Source

• Active, not recruiting

  Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

  NCT03301506· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Phenotype, Genotype & Biomarkers in ALS and Related Disorders

  NCT02327845· University of Miami· Source

• Active, not recruiting

  HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B

  NCT01796457· University of Pennsylvania· Source

• Active, not recruiting

  HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B

  NCT01298037· University of Pennsylvania· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• ALS (motor neurone disease)3 recruiting
• Atrial fibrillation1 recruiting
• Brain metastases1 recruiting
• Childhood cancers1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Frontotemporal dementia1 recruiting
• Glioblastoma1 recruiting
• Heart failure1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Meningioma1 recruiting
• Ovarian cancer1 recruiting
• Primary biliary cholangitis1 recruiting

Closed trials

• Completed

  Concomitant LAAC/AF Ablation (Watchman FLX Pro)

  NCT07041125· Heart Rhythm Clinical and Research Solutions, LLC· Source

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

  NCT06226805· Phase 2· Basking Biosciences, Inc.· Source

• Completed

  Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

  NCT06060665· Phase 3· Gilead Sciences· Source

• Recruiting

  Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  NCT05727904· Phase 3· Iovance Biotherapeutics, Inc.· Source

• Completed

  NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial

  NCT05666713· National Heart, Lung, and Blood Institute (NHLBI)· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Terminated

  Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

  NCT05237284· Phase 2· Sanofi· Source

• Completed

  A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

  NCT05006352· Phase 1· Denali Therapeutics Inc.· Source

• Completed

  Optimize PRO Study

  NCT04091048· Medtronic Cardiovascular· Source

• Terminated

  RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

  NCT03894215· Phase 2· Agenus Inc.· Source

• Completed

  Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

  NCT03070392· Phase 2· Immunocore Ltd· Source

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  CardiAMP™ Cell Therapy for Heart Failure Trial

  NCT02438306· Phase 3· BioCardia, Inc.· Source

• Completed

  Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

  NCT02360579· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Completed

  Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

  NCT01824875· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Completed

  Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

  NCT00309985· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Completed

  S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

  NCT00006721· Phase 3· SWOG Cancer Research Network· Source

• Completed

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  NCT00003641· Phase 3· ECOG-ACRIN Cancer Research Group· Source